TABLE 1.

Screening for broadly cross-neutralizing plasma samples containing anti-MPER antibodies

ParameteraValue in:
BB cohortCAPRISASAC cohort
Total no. of plasmas701868
No. (%) BCN16 (23)b4 (22)c17 (25)d
No. of BCN anti-MPER antibodies positive1126
No. of BCN anti-MPER titers > 1:1,000114
No. MPER peptide binding111
Sample analyzedBB34CAP206SAC21
  • a BCN, broadly cross-neutralizing. Anti-MPER activity was defined as neutralization of the HIV-2-HIV-1 MPER chimeric virus C1C.

  • b BCN plasmas were defined as able to neutralize at least 8 of 10 viruses tested (12).

  • c BCN plasmas were defined as able to neutralize at least 8 of 12 viruses from the tier 2 subtype C virus panel.

  • d BCN plasmas were defined as able to neutralize at least four of six viruses tested.